Stocks · News reference
Spero Therapeutics, Inc. granted equity awards to a new employee as a material inducement for their employment.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Spero Therapeutics announced that its leadership team will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference and the Jefferies Global Healthcare Conference.
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
Cantor Fitzgerald has initiated coverage on Spero Therapeutics with a price target of $6.00 per share.
Filed: 2026-10-27 AccNo: 0001193125-26-434452 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Spero Therapeutics has appointed Amy Rock as Chief Regulatory and Quality Officer and Dae Gon Ha as Senior Vice President of Corporate Development, while announcing the upcoming retirement of COO Timothy Keutzer.
The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.